Shares of Mineralys Therapeutics (MLYS.O) declined sharply today, crossing below its 20-day simple moving average (SMA) as investor sentiment turned bearish. The stock's recent closing price of $47.18 reflects a projected downside, with Wells Fargo maintaining an Overweight rating yet setting a price target of $44.62, indicating a potential 5.42% decline.
The technical breach of the 20-day SMA signals increased bearish momentum, further supported by a put/call ratio of 2.98, suggesting that investors are hedging against further declines. Despite a 5.14% increase in institutional ownership over the last quarter, which now totals 73,091K shares, major shareholders such as Catalys Pacific and Ra Capital Management have not adjusted their positions, indicating a cautious approach amidst market volatility.
As 327 funds report holdings in Mineralys, the lack of changes among top investors may reflect uncertainty in the stock's short-term performance, particularly in light of the current market outlook.
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 52.60 USD with a low forecast of 46.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 52.60 USD with a low forecast of 46.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.090
Low
46.00
Averages
52.60
High
56.00
Current: 32.090
Low
46.00
Averages
52.60
High
56.00
Stifel
Buy
maintain
$45 -> $52
2025-12-19
Reason
Stifel
Price Target
$45 -> $52
AI Analysis
2025-12-19
maintain
Buy
Reason
Stifel raised the firm's price target on Mineralys Therapeutics to $52 from $45 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst's Biopharma coverage.
BofA
Buy
maintain
$43 -> $46
2025-12-19
Reason
BofA
Price Target
$43 -> $46
2025-12-19
maintain
Buy
Reason
BofA raised the firm's price target on Mineralys Therapeutics to $46 from $43 and keeps a Buy rating on the shares after the company reported Q3 results and guided for a cash runway into 2027. A "major potential catalyst" would be Mineralys finding a commercialization and development partner, which the firm views as "necessary to maximize value," the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MLYS
Unlock Now
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$52 -> $56
2025-11-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$52 -> $56
2025-11-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Mineralys Therapeutics to $56 from $52 and keeps a Buy rating on the shares. The firm is "enthusiastic" as Mineralys heads towards the near-term application submission for its oral selective aldosterone synthase inhibitor candidate lorundrostat.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$42 -> $52
2025-10-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$42 -> $52
2025-10-30
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Mineralys Therapeutics to $52 from $42 and keeps a Buy rating on the shares. The firm says its key onion leader conversations on the unmet need for resistant and uncontrolled hypertension patients is "supportive" of lorundrostat's profile in uncontrolled and resistant hypertension.
About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
